Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Adaptive Biotechnologies Corporation - Common Stock
(NQ:
ADPT
)
14.58
+0.11 (+0.76%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Adaptive Biotechnologies Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means
↗
Today 9:12 EDT
This immune diagnostics firm reported a notable insider sale as it expands its clinical portfolio and strategic partnerships.
Via
The Motley Fool
Topics
Regulatory Compliance
Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares?
↗
April 18, 2026
This Seattle-based biotech, known for its immune medicine platform, reported a notable insider sale amid ongoing industry partnerships.
Via
The Motley Fool
Topics
Regulatory Compliance
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
April 15, 2026
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies (NASDAQ:ADPT) Reports Strong Q4 Revenue Beat and Path to Profitability
↗
February 05, 2026
Via
Chartmill
Earnings Scheduled For November 5, 2025
↗
November 05, 2025
Via
Benzinga
Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On
↗
April 08, 2026
This immuno-driven diagnostics company, known for partnerships with Genentech and Microsoft, just reported a notable insider sale.
Via
The Motley Fool
Topics
Regulatory Compliance
Adaptive Biotech's President Trimmed Her Position. But what Remains is worth a look
↗
March 30, 2026
Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale amid strong one-year stock gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Adaptive Biotech Insider Sale of 180,000 Shares Tied to Tax Event as Stock Jumps 70% in a Year
↗
March 26, 2026
Adaptive Biotechnologies, a leader in immune-driven diagnostics, saw a notable insider sale amid ongoing innovation in disease monitoring.
Via
The Motley Fool
Topics
Regulatory Compliance
Adaptive Biotechnologies Insider Sells $1 Million in Stock After a Doubling in Share Price
↗
March 26, 2026
Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale after a strong one-year stock performance.
Via
The Motley Fool
Topics
Regulatory Compliance
Adaptive Biotech (ADPT) Earnings Call Transcript
↗
February 05, 2026
Adaptive Biotech (ADPT) Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results
February 05, 2026
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
January 27, 2026
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
January 22, 2026
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization
January 13, 2026
Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that...
Via
MarketMinute
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results
January 12, 2026
Full year MRD revenue growth of 46% driven by clonoSEQ® testing volume
From
Adaptive Biotechnologies
Via
GlobeNewswire
The Year-End Biotech Chill: Adaptive Biotechnologies Braces for J.P. Morgan Crucible Amid Market Sell-Off
December 30, 2025
As the final trading days of 2025 wind down, the biotechnology sector finds itself caught in a paradoxical "bifurcated" squeeze. While the broader indices have touched record highs this year, a sharp...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 30, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
December 15, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease
December 09, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting
December 06, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting
November 24, 2025
Record-setting presence at ASH reflects widespread recognition of clonoSEQ as a standard-of-care tool for personalizing patient care and accelerating drug development
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
November 06, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results
November 05, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys
↗
November 04, 2025
Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, through three of its funds. Other key trades were also made, including buying shares in CRISPR and Beam...
Via
Benzinga
Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025
October 15, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tesla To $300? Here Are 10 Top Analyst Forecasts For Monday
↗
October 13, 2025
Via
Benzinga
A Glimpse Into The Expert Outlook On Adaptive Biotechnologies Through 4 Analysts
↗
September 30, 2025
Via
Benzinga
United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday
↗
September 30, 2025
Via
Benzinga
Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
August 27, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies (NASDAQ:ADPT) Fits Minervini's Trend Template with Strong Growth Momentum
↗
August 09, 2025
Adaptive Biotechnologies (ADPT) aligns with Minervini's trend and high-growth momentum strategies, showing strong technicals, rising earnings, and revenue growth. A top pick for trend investors.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.